2023-04-28 15:19:36
The American agency Food and Drug Administration (FDA), equivalent to Anvisa, approved this Thursday (4/27) the use of a new Pfizer vaccine against pneumococcal diseases. The vaccine is intended for children aged six weeks to 17 years.
Prevnar 20 includes 20 serotypes of the bacteria Streptococcus pneumoniae (pneumococcus), seven more than the previous version, Prevnar 13. Serotypes 8, 10A, 11A, 12F, 15B, 22F and 33F were included, which are associated with greater resistance to antibiotics, greater disease severity, greater invasive potential and prevalence in children.
The bacteria is responsible for several diseases, such as pneumonia, meningitis, sepsis, arthritis, sinusitis, otitis, conjunctivitis and bronchitis.
“One study found that the seven additional serotypes alone accounted for about 37% of invasive pneumococcal disease (IPD) in US children under five years of age,” the company states. in a statement.
“Today’s FDA approval of our vaccine, Prevnar 20, gives parents the ability to help protect their children against 20 circulating pneumococcal serotypes that represent the majority of pneumococcal disease in infants and children,” said Vice President Annaliesa Anderson, Senior Chief Scientific Officer of Vaccine Research and Development at Pfizer.
Get news from metropolises on your Telegram and stay on top of everything! Just access the channel: https://t.me/metropolesurgente.
1682807747
#Approves #NextGeneration #Pneumococcal #Vaccine #metropolises